Circadin® – prolonged release melatonin for insomnia is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

Indicaton

Insomnia

Therapeutic indications

Type of product

Small molecule

Table

Phase

Marketed

You may also be interested in

Dipraglurant (mGlu5 NAM) for PD-LID

Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

Phase II started

nizubaglustat

Has the potential to treat multiple rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses, and Niemann-Pick disease type C (NPC).

Phase II started

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed